Evidence map›Paper›PMID 29944649›Full record

ArticlePLoS medicine2018

Antibiotic prophylaxis-Preventing severe infections and saving lives in poor countries with very high mortality risk.

Keith P Klugman, Rasa Izadnegahdar

Abstract readComment
In one paragraph

Article in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Keith P KlugmanPneumonia Program Strategy Team, Bill and Melinda Gates Foundation, Seattle, Washington, United States of America.ORCID 0000-0001-6637-728X
Rasa IzadnegahdarMaternal Neonatal, Child Health Discovery and Tools Program Strategy Team, Bill and Melinda Gates Foundation, Seattle, Washington, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a Perspective, Keith P. Klugman and Rasa Izadnegahdar from the Bill and Melinda Gates Foundation discuss the potentials and risks of antibiotic prophylaxis interventions for infectious disease outbreaks in rural regions, such as sub-Saharan Africa with very high mortality rates, when primary prophylactic vaccination programs are not yet available.

Indexed as

CiprofloxacinMeningitis, MeningococcalAfrica South of the SaharaAntibiotic ProphylaxisHumansCiprofloxacin

Identifiers

PMID29944649
PMCPMC6019101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.